

**S3 Table.** Post-consolidation: standard risk

<b>Drug</b>	<b>Dose</b>	<b>Days</b>
<b>Interim maintenance (11 wk)</b>		
Vincristine (IV)	1.5 mg/m <sup>2</sup> (max. 2 mg)	1, 15, 29
Methotrexate (IV)	5 g/m <sup>2</sup>	1, 15, 29
6-Mercaptopurine (PO)	60 mg/m <sup>2</sup>	43-77
Methotrexate (IT)	By age <sup>a)</sup>	1, 15, 29
<b>Delayed intensification (8 wk)</b>		
Vincristine (IV)	1.5 mg/m <sup>2</sup> (max. 2mg)	1, 15, 29, 43
Daunorubicin (IV)	30 mg/m <sup>2</sup>	1, 15, 29, 43
Cytarabine (IV)	100 mg/m <sup>2</sup>	1-5, 29-33
Cyclophosphamide (IV)	1,200 mg/m <sup>2</sup>	15, 43
l-Asparaginase (IM)	6,000 u/m <sup>2</sup> (max, 10,000 u)	16, 18, 20, 44, 46, 48
Prednisolone (PO)	45 mg/m <sup>2</sup> (max. 60 mg)	1-5, 15-19, 29-33, 43-47
Methotrexate (IT)	By age <sup>3</sup>	1, 29

Schema: IM#1 (HD-MTX x3) → DI#1 → Maint. DI, delayed intensification; HD-MTX, high dose methotrexate; IM, intramuscularly; IT, intrathecal; IV, intravenous; Maint., maintenance; PO, per os. <sup>a)</sup>Age-adjusted doses of intrathecal methotrexate: 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years).